Myriad Genetics Inc (MYGN) 20.75 $MYGN
Services Stocks on Investors' Radar -- HERC, Myriad Genetics, Qiagen, and INC Research
PR Newswire - Wed Sep 21, 6:30AM CDT
Today, Stock-Callers reviews the performance of these services stocks: HERC Holdings Inc. (NYSE: HRI), Myriad Genetics Inc. (NASDAQ: MYGN), Qiagen NV (NASDAQ: QGEN), and INC Research Holdings Inc. (NASDAQ: INCR). At the close of Tuesday's trading session, the NASDAQ Composite ended the trading session at 5,241.35, up 0.12%; the Dow Jones Industrial Average edged 0.05% higher, to finish at 18,129.96; and the S&P 500 closed at 2,139.76, up 0.03%. Learn more about these stocks by accessing their free research reports at:
MYGN: 20.75 (-0.01), INCR: 43.88 (+0.72), HRI: 32.91 (+0.29), QGEN: 26.45 (+0.26)
Shares of MYGN Down 39.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Sep 19, 1:05PM CDT
SmarTrend identified a Downtrend for Myriad Genetics (NASDAQ:MYGN) on May 4th, 2016 at $34.70. In approximately 5 months, Myriad Genetics has returned 39.05% as of today's recent price of $21.15.
MYGN: 20.75 (-0.01)
SmarTrend Watching for Potential Pullback in Shares of Myriad Genetics After 4.06% Gain
Comtex SmarTrend(R) - Wed Sep 14, 3:25PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $20.82 to a high of $21.82. Yesterday, the shares gained 4.1%, which took the trading range above the 3-day high of $21.03 on volume of 758,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYGN: 20.75 (-0.01)
Myriad Genetics Rises 4.06% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Sep 14, 3:24PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $20.82 to a high of $21.82. Yesterday, the shares gained 4.1%, which took the trading range above the 3-day high of $21.03 on volume of 758,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYGN: 20.75 (-0.01)
Myriad Genetics' TruCulture Study Results Favorable
Zacks Equity Research - Zacks Investment Research - Mon Sep 12, 8:28AM CDT
Myriad RBM, a part of Myriad Genetics (MYGN) recently announced the release of positive data from Milieu Interieur Project which is based on its TruCulture platform.
MYGN: 20.75 (-0.01), GWPH: 107.96 (-0.33), QDEL: 21.88 (-1.03), NUVA: 67.00 (+0.11)
Shares of MYGN Down 40.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Sep 09, 1:06PM CDT
SmarTrend identified a Downtrend for Myriad Genetics (NASDAQ:MYGN) on May 4th, 2016 at $34.70. In approximately 4 months, Myriad Genetics has returned 40.84% as of today's recent price of $20.53.
MYGN: 20.75 (-0.01)
Myriad RBM's TruCulture(R) and Gene Expression Profiling Characterizes Immune Responses in Landmark Study Led by Institut Pasteur
GlobeNewswire - Wed Sep 07, 6:05AM CDT
Myriad RBM, Inc., a wholly owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN) a global leader in personalized medicine, announced today that researchers from the Institut Pasteur have published new landmark research from the Milieu Interieur Project relating to the ability to perform standardized transcriptome profiling based upon a variety of immune stimuli in the August issue of Cell Reports. The study looked at the expression levels of different genes in 25 subjects following TruCulture incubation with twenty clinically relevant immune system stimulants. The research demonstrated that expression levels from as few as 44 of the 572 genes tested could segregate responses from the various stimuli and reveal variations in immune response.
MYGN: 20.75 (-0.01)
Myriad Genetics Adds Assurex Health, Grows in Neuroscience
Zacks Equity Research - Zacks Investment Research - Tue Sep 06, 3:36PM CDT
Myriad Genetics, Inc. (MYGN) recently closed its earlier announced acquisition of Assurex Health.
MYGN: 20.75 (-0.01), HSKA: 54.50 (-1.18), ANIP: 65.12 (+0.28), ANIK: 47.93 (+0.34)
Downtrend Call Working As Myriad Genetics Stock Falls 41.1% (MYGN)
Comtex SmarTrend(R) - Fri Sep 02, 12:52AM CDT
SmarTrend identified a Downtrend for Myriad Genetics (NASDAQ:MYGN) on May 4th, 2016 at $34.70. In approximately 4 months, Myriad Genetics has returned 41.10% as of today's recent price of $20.44.
MYGN: 20.75 (-0.01)
Myriad Genetics Completes Acquisition of Assurex Health
GlobeNewswire - Thu Sep 01, 3:05PM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN) a global leader in personalized medicine, announced today that it has completed its acquisition of Assurex Health effective August 31, 2016. Assurex Health, which is based in Mason, Ohio, is an informatics-based precision medicine company providing treatment decision support to healthcare providers for mental health patients.
MYGN: 20.75 (-0.01)
Myriad Genetics to Present at the 2016 Morgan Stanley Global Healthcare Conference
GlobeNewswire - Tue Aug 30, 3:05PM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 2016 Morgan Stanley Global Healthcare Conference at 9:20 a.m. ET on September 12, 2016, at the Grand Hyatt New York in New York City.
MYGN: 20.75 (-0.01), MS: 31.92 (+0.22)
Medical Device Leader Series: Top Companion Diagnostics (CDx) Developers, Manufacturers and Marketers in 2016
PR Newswire Europe - Wed Aug 24, 8:02AM CDT
LONDON, August 24, 2016 /PRNewswire/ --
JNJ: 118.91 (+0.96), ABT: 41.92 (+0.34), MYGN: 20.75 (-0.01), A: 46.04 (+0.33)
Weakness Seen in Myriad Genetics (MYGN) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 6:59AM CDT
Myriad Genetics (MYGN) should not be considered as it holds an unfavorable Zacks Rank and it has seen negative earnings estimate revisions.
MYGN: 20.75 (-0.01), CBM: 46.77 (+0.78)
Myriad Genetics: Q4 Hit by Low Test Revenues, Gross Margin
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 7:38AM CDT
Myriad (MYGN) ended fiscal 2016 on a disappointing note, with its fourth-quarter numbers missing the Zacks Consensus Estimate on both fronts.
MYGN: 20.75 (-0.01), HSKA: 54.50 (-1.18), ANIP: 65.12 (+0.28), ANIK: 47.93 (+0.34)
Myriad Genetics (MYGN) in Focus: Stock Up 5.6% in Session
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 7:35AM CDT
Myriad Genetics, Inc. (MYGN) was a big mover last session, as the company saw its shares rise around 6% on the day.
MYGN: 20.75 (-0.01), ANIP: 65.12 (+0.28)
Downgrade Alert for Myriad Genetics (MYGN)
Comtex SmarTrend(R) - Thu Aug 11, 3:54AM CDT
Myriad Genetics (NASDAQ:MYGN) was downgraded from Buy to Hold at Gabelli & Co today. The stock closed yesterday at $19.70 on volume of 19.0 million shares, above average daily volume of 853,000. Myriad Genetics, Inc. develops and markets molecular diagnostic products to provide physicians with information to help guide the care of their patients, to prevent disease, delay the onset of disease, or catch disease at an early stage.
MYGN: 20.75 (-0.01)
Services Stocks on Investors' Radar -- HERC, Myriad Genetics, Qiagen, and INC Research
PR Newswire - Wed Sep 21, 6:30AM CDT
Today, Stock-Callers reviews the performance of these services stocks: HERC Holdings Inc. (NYSE: HRI), Myriad Genetics Inc. (NASDAQ: MYGN), Qiagen NV (NASDAQ: QGEN), and INC Research Holdings Inc. (NASDAQ: INCR). At the close of Tuesday's trading session, the NASDAQ Composite ended the trading session at 5,241.35, up 0.12%; the Dow Jones Industrial Average edged 0.05% higher, to finish at 18,129.96; and the S&P 500 closed at 2,139.76, up 0.03%. Learn more about these stocks by accessing their free research reports at:
MYGN: 20.75 (-0.01), INCR: 43.88 (+0.72), HRI: 32.91 (+0.29), QGEN: 26.45 (+0.26)
Shares of MYGN Down 39.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Sep 19, 1:05PM CDT
SmarTrend identified a Downtrend for Myriad Genetics (NASDAQ:MYGN) on May 4th, 2016 at $34.70. In approximately 5 months, Myriad Genetics has returned 39.05% as of today's recent price of $21.15.
MYGN: 20.75 (-0.01)
SmarTrend Watching for Potential Pullback in Shares of Myriad Genetics After 4.06% Gain
Comtex SmarTrend(R) - Wed Sep 14, 3:25PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $20.82 to a high of $21.82. Yesterday, the shares gained 4.1%, which took the trading range above the 3-day high of $21.03 on volume of 758,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYGN: 20.75 (-0.01)
Myriad Genetics Rises 4.06% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Sep 14, 3:24PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $20.82 to a high of $21.82. Yesterday, the shares gained 4.1%, which took the trading range above the 3-day high of $21.03 on volume of 758,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYGN: 20.75 (-0.01)
Myriad Genetics' TruCulture Study Results Favorable
Zacks Equity Research - Zacks Investment Research - Mon Sep 12, 8:28AM CDT
Myriad RBM, a part of Myriad Genetics (MYGN) recently announced the release of positive data from Milieu Interieur Project which is based on its TruCulture platform.
MYGN: 20.75 (-0.01), GWPH: 107.96 (-0.33), QDEL: 21.88 (-1.03), NUVA: 67.00 (+0.11)
Shares of MYGN Down 40.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Sep 09, 1:06PM CDT
SmarTrend identified a Downtrend for Myriad Genetics (NASDAQ:MYGN) on May 4th, 2016 at $34.70. In approximately 4 months, Myriad Genetics has returned 40.84% as of today's recent price of $20.53.
MYGN: 20.75 (-0.01)
Myriad RBM's TruCulture(R) and Gene Expression Profiling Characterizes Immune Responses in Landmark Study Led by Institut Pasteur
GlobeNewswire - Wed Sep 07, 6:05AM CDT
Myriad RBM, Inc., a wholly owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN) a global leader in personalized medicine, announced today that researchers from the Institut Pasteur have published new landmark research from the Milieu Interieur Project relating to the ability to perform standardized transcriptome profiling based upon a variety of immune stimuli in the August issue of Cell Reports. The study looked at the expression levels of different genes in 25 subjects following TruCulture incubation with twenty clinically relevant immune system stimulants. The research demonstrated that expression levels from as few as 44 of the 572 genes tested could segregate responses from the various stimuli and reveal variations in immune response.
MYGN: 20.75 (-0.01)
Myriad Genetics Adds Assurex Health, Grows in Neuroscience
Zacks Equity Research - Zacks Investment Research - Tue Sep 06, 3:36PM CDT
Myriad Genetics, Inc. (MYGN) recently closed its earlier announced acquisition of Assurex Health.
MYGN: 20.75 (-0.01), HSKA: 54.50 (-1.18), ANIP: 65.12 (+0.28), ANIK: 47.93 (+0.34)
Downtrend Call Working As Myriad Genetics Stock Falls 41.1% (MYGN)
Comtex SmarTrend(R) - Fri Sep 02, 12:52AM CDT
SmarTrend identified a Downtrend for Myriad Genetics (NASDAQ:MYGN) on May 4th, 2016 at $34.70. In approximately 4 months, Myriad Genetics has returned 41.10% as of today's recent price of $20.44.
MYGN: 20.75 (-0.01)
Myriad Genetics Completes Acquisition of Assurex Health
GlobeNewswire - Thu Sep 01, 3:05PM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN) a global leader in personalized medicine, announced today that it has completed its acquisition of Assurex Health effective August 31, 2016. Assurex Health, which is based in Mason, Ohio, is an informatics-based precision medicine company providing treatment decision support to healthcare providers for mental health patients.
MYGN: 20.75 (-0.01)
Myriad Genetics to Present at the 2016 Morgan Stanley Global Healthcare Conference
GlobeNewswire - Tue Aug 30, 3:05PM CDT
Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 2016 Morgan Stanley Global Healthcare Conference at 9:20 a.m. ET on September 12, 2016, at the Grand Hyatt New York in New York City.
MYGN: 20.75 (-0.01), MS: 31.92 (+0.22)
Medical Device Leader Series: Top Companion Diagnostics (CDx) Developers, Manufacturers and Marketers in 2016
PR Newswire Europe - Wed Aug 24, 8:02AM CDT
LONDON, August 24, 2016 /PRNewswire/ --
JNJ: 118.91 (+0.96), ABT: 41.92 (+0.34), MYGN: 20.75 (-0.01), A: 46.04 (+0.33)
Weakness Seen in Myriad Genetics (MYGN) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 6:59AM CDT
Myriad Genetics (MYGN) should not be considered as it holds an unfavorable Zacks Rank and it has seen negative earnings estimate revisions.
MYGN: 20.75 (-0.01), CBM: 46.77 (+0.78)
Myriad Genetics: Q4 Hit by Low Test Revenues, Gross Margin
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 7:38AM CDT
Myriad (MYGN) ended fiscal 2016 on a disappointing note, with its fourth-quarter numbers missing the Zacks Consensus Estimate on both fronts.
MYGN: 20.75 (-0.01), HSKA: 54.50 (-1.18), ANIP: 65.12 (+0.28), ANIK: 47.93 (+0.34)
Myriad Genetics (MYGN) in Focus: Stock Up 5.6% in Session
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 7:35AM CDT
Myriad Genetics, Inc. (MYGN) was a big mover last session, as the company saw its shares rise around 6% on the day.
MYGN: 20.75 (-0.01), ANIP: 65.12 (+0.28)
Downgrade Alert for Myriad Genetics (MYGN)
Comtex SmarTrend(R) - Thu Aug 11, 3:54AM CDT
Myriad Genetics (NASDAQ:MYGN) was downgraded from Buy to Hold at Gabelli & Co today. The stock closed yesterday at $19.70 on volume of 19.0 million shares, above average daily volume of 853,000. Myriad Genetics, Inc. develops and markets molecular diagnostic products to provide physicians with information to help guide the care of their patients, to prevent disease, delay the onset of disease, or catch disease at an early stage.
MYGN: 20.75 (-0.01)
